Vertex Pharmaceuticals closed at $522.38, up 1.17% from the prior session even as the S&P 500 slipped 0.03%. The drugmaker is expected to report quarterly EPS of $4.84, up 0.83% from the prior-year quarter, on revenue of $3.4 billion, up 10.43% year over year, according to the Zacks Consensus Estimate. For the full year, consensus estimates project earnings of $18.86 per share and revenue of $13.21 billion, representing changes of +2.5% and +10.08%, respectively, from the preceding year. Over the past month the consensus EPS estimate has shifted 1.04% downward, and Vertex Pharmaceuticals currently carries a Zacks Rank of #3 (Hold). The stock trades at a Forward P/E ratio of 27.38, a premium to its industry's average of 25.2, with a PEG ratio of 2 versus an industry average of 1.91.
Vertex Pharmaceuticals IncConsensus estimates project Vertex's quarterly EPS up 0.83% and revenue up 10.43% year over year, with full-year growth expected.
